Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
Neoadjuvant therapy
Oesophageal neoplasms
Pathology, Surgical
Positron emission tomography-computed tomography
Surgical oncology
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
13
07
2022
accepted:
27
01
2023
revised:
23
11
2022
medline:
25
4
2023
pubmed:
16
3
2023
entrez:
15
3
2023
Statut:
ppublish
Résumé
2-deoxy-2[ Cohort study of 75 patients with oesophageal or oesophago-gastric junction (GOJ) adenocarcinoma treated with neoadjuvant chemotherapy then surgery at Guy's and St Thomas' NHS Foundation Trust, London (2017-2020). Standardised uptake value (SUV) metrics on pre- and post-treatment FDG PET-CT in the primary tumour (mTR) and loco-regional lymph nodes (mNR) were derived. Optimum SUV Optimum tumour SUV Metabolic tumour and nodal response predicted pTR and pNR, respectively, in patients with oesophageal or GOJ adenocarcinoma. However, currently utilised response criteria may not be optimal. pTR, mTR, pNR and mNR were independent predictors of survival. • FDG PET-CT has an emerging role in evaluating response to neoadjuvant therapy in patients with oesophageal cancer. • Prospective cohort study demonstrated that metabolic response in the primary tumour and lymph nodes was predictive of pathological response in a cohort of patients with adenocarcinoma of the oesophagus or oesophago-gastric junction treated with neoadjuvant chemotherapy followed by surgical resection. • Patients who demonstrated a response to neoadjuvant chemotherapy in the primary tumour or lymph nodes on FDG PET-CT demonstrated better survival and reduced rates of tumour recurrence.
Identifiants
pubmed: 36920518
doi: 10.1007/s00330-023-09482-7
pii: 10.1007/s00330-023-09482-7
pmc: PMC10121512
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3647-3659Investigateurs
A Jacques
(A)
N Griffin
(N)
V Goh
(V)
S Ngan
(S)
K Owczarczyk
(K)
A Sita-Lumsden
(A)
A Qureshi
(A)
F Chang
(F)
U Mahadeva
(U)
B Gill-Barman
(B)
S George
(S)
M Ong
(M)
J Waters
(J)
M Cominos
(M)
T Sevitt
(T)
O Hynes
(O)
G Tham
(G)
J M Dunn
(JM)
S S Zeki
(SS)
Informations de copyright
© 2023. The Author(s).
Références
Miyata H, Yamasaki M, Makino T et al (2016) Impact of number of [18F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer. Br J Surg 103(1):97–104. https://doi.org/10.1002/BJS.9965
doi: 10.1002/BJS.9965
pubmed: 26506079
Findlay JM, Gillies RS, Franklin JM et al (2016) Restaging oesophageal cancer after neoadjuvant therapy with 18F-FDG PET-CT: identifying interval metastases and predicting incurable disease at surgery. Eur Radiol 26(10):3519–3533. https://doi.org/10.1007/S00330-016-4227-4
doi: 10.1007/S00330-016-4227-4
pubmed: 26883329
Findlay JM, Bradley KM, Wang LM et al (2017) Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. Br J Surg 104(4):408–417. https://doi.org/10.1002/bjs.10611
doi: 10.1002/bjs.10611
pubmed: 28093719
Foley K, Findlay J, Goh V (2018) Novel imaging techniques in staging oesophageal cancer. Best Pract Res Clin Gastroenterol 36–37:17–25. https://doi.org/10.1016/j.bpg.2018.11.009
doi: 10.1016/j.bpg.2018.11.009
pubmed: 30551852
Findlay JM, Bradley KM et al (2017) Predicting pathologic response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalized therapy. J Nucl Med 58(2):266–275. https://doi.org/10.2967/JNUMED.116.176313
doi: 10.2967/JNUMED.116.176313
pubmed: 27635027
Davies AR, Myoteri D, Zylstra J et al (2018) Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. Br J Surg 105(12):1639–1649. https://doi.org/10.1002/bjs.10900
doi: 10.1002/bjs.10900
pubmed: 30047556
Evans RP, Kamarajah SK, Kunene V, et al. Impact of neoadjuvant chemotherapy on nodal regression and survival in oesophageal adenocarcinoma. Eur J Surg Oncol. 2022;0(0). https://doi.org/10.1016/J.EJSO.2021.12.021
Noorani A, Li X, Goddard M, Crawte J et al (2020) Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat Genet 52(1):74. https://doi.org/10.1038/S41588-019-0551-3
doi: 10.1038/S41588-019-0551-3
pubmed: 31907488
pmcid: 7100916
Lordick F, Ott K, Krause BJ et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8(9):797–805. https://doi.org/10.1016/S1470-2045(07)70244-9
doi: 10.1016/S1470-2045(07)70244-9
pubmed: 17693134
Wahl RL, Jacene H, Kasamon Y et al (2009) Response criteria in solid tumors. J Nucl Med 50(Suppl 1):122–150. https://doi.org/10.2967/jnumed.108.057307
doi: 10.2967/jnumed.108.057307
Weber WA, Ott K, Becker K et al (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19(12):3058–3065. https://doi.org/10.1200/JCO.2001.19.12.3058
doi: 10.1200/JCO.2001.19.12.3058
pubmed: 11408502
Union for International Cancer Control (UICC). TNM classification of malignant tumours - eighth edition. J B, editor. Wiley Blackwell
Siewert JR, Stein HJ. Carcinoma of the gastroesophageal junction - classification , pathology and extent of resection Tumor Type Adeno Ca of the Distal Esophagus True Ca Cardia Anatomical. 1996;173–82
Mandard FJ , Dalibard JC, Mandard J, et al. 1994 Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic Correlations. Cancer.73(11)
Textor J, Van Der Zander B, Gilthorpe MS, et al. Software application profile robust causal inference using directed acyclic graphs: the R package “dagitty”; https://doi.org/10.1093/ije/dyw341
Downey RJ, Akhurst T, Ilson D et al (2003) Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21(3):428–432. https://doi.org/10.1200/JCO.2003.04.013
doi: 10.1200/JCO.2003.04.013
pubmed: 12560430
Kim MK, Ryu JS, Kim SB et al (2007) Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43(9):1385–1391. https://doi.org/10.1016/J.EJCA.2007.04.001
doi: 10.1016/J.EJCA.2007.04.001
pubmed: 17512192
Gillies RS, Middleton MR, Blesing C et al (2012) Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer. Eur Radiol 22(9):2035–2043. https://doi.org/10.1007/S00330-012-2459-5
doi: 10.1007/S00330-012-2459-5
pubmed: 22562089
Ott K, Weber WA, Lordick F et al (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24(29):4692–4698. https://doi.org/10.1200/JCO.2006.06.7801
doi: 10.1200/JCO.2006.06.7801
pubmed: 16966684
Goodman KA, Ou FS, Hall NC et al (2021) Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) Trial. J Clin Oncol 39(25):2803–2815. https://doi.org/10.1200/JCO.20.03611
doi: 10.1200/JCO.20.03611
pubmed: 34077237
pmcid: 8407649